recist.eortc.orgRECIST - Response Evaluation Criteria in Solid Tumors

Donate Academic Groups Area Working Group Our mission Steering committee Working group Supporting staff Terms of Reference Tools i 1.1 Work in progress for targeted agents? Is there a role for FDG-PET? in pediatric trials? Response assessment in patients with brain metastases Publications Acknowledgements Contact Working Group - Our mission - Steering committee - Working group - Supporting staff - Terms of Reference Tools - i - 1.1 Work in progress - for targeted agents? - Is there a role for FDG-PET? - in pediatric trials? - Response assessment in patients with brain metastases Publications Acknowledgements Contact (Response Evaluation Criteria in Solid Tumours) provides a simple and pragmatic methodology to evaluate the activity and efficacy of new cancer therapeutics in solid tumors, using validated and consistent criteria to assess changes in tumor burden. The Working Group comprises representatives of the European Organization for Research and Treatment of Cancer (EORTC), National Cancer Institute (NCI) of the United States and Canadian Cancer Trials Group (CCTG), as well as several pharmaceutical companies. Its mission is to ensures that undergoes continued testing, validation and updating. disease assessment is effective for targeted treatment as well as classical chemotherapy By Frédéric October 11, 2019 Assessing tumour growth and cancer cell proliferation in patients is important both for judging the effectiveness of individual treatment and for the evaluation of therapies in clinical trials. EORTC was among the international organisations that developed (Response Evaluation Criteria in Solid Tumours), a method of determining whether tumour measurement data can allow the conclusion Read More Introducing i: modified guideline for immunotherapy By pruyskart January 25, 2017 The i guideline addresses the singularities of immunotherapies, ensuring consistent trial design and interpretation of tumour progression measurements for immune modulators. The guideline takes into account distinctive behaviours linked to these types of therapeutics, such as delayed responses after pseudoprogression, and describes a standard approach to solid tumour measurement and definitions for objective change in tumour Read More Assessing to prepare for new clinical trial models By pruyskart January 16, 2017 The Working Group published their view on the continued relevance of guidelines and on the challenges to maintain as a standard for the assessment of tumour burden in clinical trials. While we recognise that cannot accommodate all possible protocol specificities, it remains the only general tool that provides harmonisation of tumour Read More 1.1 – Adapting and updating guidelines to improve the assessment of outcomes By pruyskart June 24, 2016 Hear Larry Schwartz summarize the latest work from the Working Group. One focuses on clarifying the interpretation of 1.1, and one provides a summary of current widely accepted alternatives to in certain specific disease settings. In1.1 – Update and Clarification: From the Committee”, the working group has summarized frequently Read More Disclaimer The primary intent of the website is to communicate efforts being made to refine response evaluation criteria and also the development of new evaluation criteria that can be used for targeted agents and with imaging technologies. The content of this website is the property of the Working Group. Read more Canadian Cancer Trial Group Groupe canadien des essais sur le cancer © |...